Management of Cytokine Release Syndrome in AML Patients Treated with Flotetuzumab, a CD123 x CD3 Bispecific Dart® Molecule for T-Cell Redirected Therapy

被引：9

作者：

Jacobs, Kenneth ^{[1
]}

Viero, Cedric ^{[2
]}

Godwin, John ^{[3
]}

Baughman, Jan ^{[4
]}

Sun, Jichao ^{[1
]}

Ying, Kang ^{[1
]}

Muth, John ^{[1
]}

Hong, Shengyan ^{[1
]}

Vey, Norbert ^{[5
]}

Sweet, Kendra L. ^{[6
]}

Uy, Geoffrey L. ^{[7
]}

Ravandi, Farhad ^{[8
]}

Foster, Matthew C. ^{[9
]}

Rizzieri, David A. ^{[10
]}

Arellano, Martha L. ^{[11
]}

Rettig, Michael P. ^{[12
]}

Topp, Max S. ^{[13
]}

Huls, Gerwin ^{[14
]}

Lelievre, Helene ^{[2
]}

Paolini, Stefania ^{[15
]}

Ciceri, Fabio ^{[16
]}

Carrabba, Matteo Giovanni ^{[17
]}

Lowenberg, Bob ^{[18
]}

DiPersio, John F. ^{[12
]}

Wigginton, Jon ^{[1
]}

Davidson-Moncada, Jan K. ^{[19
]}

机构：

[1] MacroGenics Inc, Rockville, MD USA

[2] Servier, Paris, France

[3] Providence Portland Med Ctr, Portland, OR USA

[4] MacroGenics Inc, San Francisco, CA USA

[5] Inst Paoli Calmettes, Dept Hematol, Marseille, France

[6] H Lee Moffitt Canc Ctr & Res Inst, Malignant Hematol Dept, Tampa, FL USA

[7] Washington Univ, Sch Med, St Louis, MO USA

[8] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[9] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA

[10] Duke Univ, Med Ctr, Dept Med, Div Hematol Malignancies & Cellular Therapy, Durham, NC 27710 USA

[11] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[12] Washington Univ, Sch Med, Dept Internal Med, Div Oncol, St Louis, MO 63110 USA

[13] Univ Klinikum Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany

[14] Univ Med Ctr Groningen, Hematol, Groningen, Netherlands

[15] Univ Bologna, Inst Hematol L&A Seragnoli, Dept Expt Diagnost & Specialty Med, Bologna, Italy

[16] Ist Sci San Raffaele, Hematol & Bone Marrow Transplantat Unit, Milan, Italy

[17] IRCCS San Raffaele Sci Inst, Hematol & Bone Marrow Transplantat Unit, Milan, Italy

[18] Erasmus Univ, Med Ctr, Dept Hematol, Rotterdam, Netherlands

[19] MacroGenics Inc, Washington, DC USA

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-99-112615

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2738

引用

页数：4

共 50 条

[21] A phase I, first-in-human study of MGD006/S80880 (CD123 x CD3 DART) in AML/MDS.
Vey, Norbert
Davidson-Moncada, Jan Kenneth
Uy, Geoffrey L.
Rizzieri, David
Khoury, Hanna Jean
Foster, Matthew Charles
Godwin, John E.
Topp, Max S.
Martinelli, Giovanni
Ciceri, Fabio
Carrabba, Matteo Giovanni
Huls, Gerwin A.
Wegener, Antje
Tran, Kathy C.
Shannon, Michele
Sun, Jichao
Wigginton, Jon M.
DiPersio, John F.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[22] Combinatorial Anti-Tumor Activity in Animal Models of a Novel CD123 x CD3 Bispecific Dart® Molecule (MGD024) with Cytarabine, Venetoclax or Azacitidine Supports Combination Therapy in Acute Myeloid Leukemia
Alderson, Ralph F.
Huang, Ling
Zhang, Xiayu
Li, Haiquan
Kaufman, Thomas
Diedrich, Gundo
Moore, Paul
Bonvini, Ezio
BLOOD, 2021, 138
[23] A CD3 x FRα T-cell engaging bispecific antibody for efficient killing of ovarian cancer cells with minimal cytokine release.
Buelow, Ben
Avanzino, Brian
Balasubramani, Aarti
Boudreau, Andrew
Davison, Laura
Ganesan, Priya
Harris, Katherine
Hartstein, Sharon
Malik-Chaudhry, Harbani
Pham, Duy
Prabhakar, Kirthana
Rangaswamy, Udaya
Saiganesh, Sowmya
Schellenberger, Ute
Ugamraj, Harshad
Kehm, Hannes
Trinklein, Nathan
Iyer, Suhasini
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[24] Generation of a novel ROR1 x CD3 bispecific T-cell engager for better tumor killing and minimal cytokine release
Wu, Danqing
Gong, Shiyong
Wu, Xuan
Naren, Gaowa
Dong, Liqin
Lensky, Stephan
Wu, Chengbin
CANCER RESEARCH, 2024, 84 (07)
[25] Enhanced efficacy of redirected T-cell therapy of TNBC with a Trop-2/CD3 bispecific antibody in combination with a checkpoint inhibitor
Rossi, E. A.
Chang, K.
Cardillo, T. M.
Rossi, D. L.
Li, R.
Mostafa, A.
Sharkey, R. M.
Goldenberg, D. M.
CANCER RESEARCH, 2017, 77
[26] CD3 bispecific antibody-induced cytokine release is dispensable for cytotoxic T cell activity
Li, Ji
Piskol, Robert
Ybarra, Ryan
Chen, Ying-Jiun J.
Li, Jason
Slaga, Dionysos
Hristopoulos, Maria
Clark, Robyn
Modrusan, Zora
Totpal, Klara
Junttila, Melissa R.
Junttila, Teemu T.
SCIENCE TRANSLATIONAL MEDICINE, 2019, 11 (508)
[27] T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors
Middelburg, Jim
Sluijter, Marjolein
Schaap, Gaby
Goynuk, Busra
Lloyd, Katy
Ovcinnikovs, Vitalijs
Zom, Gijs G.
Marijnissen, Renoud J.
Groeneveldt, Christianne
Griffioen, Lisa
Sandker, Gerwin G. W.
Heskamp, Sandra
van der Burg, Sjoerd H.
Arakelian, Tsolere
Ossendorp, Ferry
Arens, Ramon
Schuurman, Janine
Kemper, Kristel
van Hall, Thorbald
NATURE COMMUNICATIONS, 2024, 15 (01)
[28] T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors
Jim Middelburg
Marjolein Sluijter
Gaby Schaap
Büşra Göynük
Katy Lloyd
Vitalijs Ovcinnikovs
Gijs G. Zom
Renoud J. Marijnissen
Christianne Groeneveldt
Lisa Griffioen
Gerwin G. W. Sandker
Sandra Heskamp
Sjoerd H. van der Burg
Tsolere Arakelian
Ferry Ossendorp
Ramon Arens
Janine Schuurman
Kristel Kemper
Thorbald van Hall
Nature Communications, 15
[29] Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436
Uckun, Fatih M.
Watts, Justin
Mims, Alice S.
Patel, Prapti
Wang, Eunice
Shami, Paul J.
Cull, Elizabeth
Lee, Cynthia
Cogle, Christopher R.
Lin, Tara L.
CANCERS, 2021, 13 (21)
[30] Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of XmAb14045, a CD123 x CD3 T Cell-Engaging Bispecific Antibody: Initial Results of a Phase 1 Study
Ravandi, Farhad
Bashey, Asad
Foran, James M.
Stock, Wendy
Mawad, Raya
Blum, William
Saville, M. Wayne
Johnson, Chelsea M.
Vanasse, K. Gary J.
Ly, Thomas
Kantarjian, Hagop M.
Bhatnagar, Bhavana
Takahashi, Koichi
Mims, Alice S.
BLOOD, 2018, 132

← 1 2 3 4 5 →